← Eichor
Study identifier: NCT07547436 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Condition: Non-cystic Fibrosis Bronchiectasis  ·  Sponsor: Sanofi

PhasePhase 2
Planned participants70
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).

This description comes directly from the study's public registry record.

Talk to the study team

Trial Transparency email recommended (Toll free for US & Canada)  ·  800-633-1610  ·  Contact-US@sanofi.com

Always discuss trial participation with your own doctor first.

Locations (4)

Pulmonary Associates - Phoenix - East McDowell Road- Site Number : 8400008Phoenix, Arizona, United StatesRecruiting
Advanced Pulmonary Research Institute- Site Number : 8400001Loxahatchee Groves, Florida, United StatesRecruiting
Hull and Hull Medical Specialists- Site Number : 8400002Plantation, Florida, United StatesRecruiting
Clinical Research Associates of Central Pennsylvania- Site Number : 8400006DuBois, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07547436